The study followed nearly 17 million people, the majority of whom were in the 26-75 age range, and found that after climbing steadily since 2013, rates of obesity in the U.S. fell 0.15% in 2023, according to a research letter published in the Journal of the American Medical Association (JAMA) on Dec. 13.

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like Ozempic and Wegovy, according to the study authors.

Obesity dipped in U.S. adults last year for the first time in more than a decade, research found. That might be due, in part, to weight loss drugs like Ozempic.

U.S. obesity rates have decreased for the first time in more than a decade, with new weight loss medications potentially playing a role in the turnaround.

Amazing '90s Movies That Everyone Seems To Have Forgotten Bryson DeChambeau and Rory McIlroy trade jabs in Vegas ahead of historic $10million Crypto Showdown 7 signs it’s time to end a friendship Mona

Obesity rates in the US dropped slightly in 2023 for the first time in over a decade, with rates falling from 46% to 45.6%. A key driver of this trend is the increased use of semaglutide, the active ingredient in weight loss drugs like Ozempic and Wegovy.

A new study reveals a slight drop in U.S. obesity rates, driven by weight loss drugs, lifestyle changes post-COVID, and regional trends. Experts caution that long-term impacts remain uncertain despite this encouraging sign.